Blockchain Registration Transaction Record

Regentis Biomaterials Plans European Surgeon Training for GelrinC Rollout

Regentis Biomaterials (NYSE American: RGNT) announces surgeon training for GelrinC, a CE Mark-approved knee cartilage treatment, starting Q3 2026 in Europe.

This news matters because knee cartilage lesions affect millions globally, and current treatment options often involve invasive surgeries or cell-based therapies that are not widely accessible. GelrinC offers a cell-free, off-the-shelf solution that simplifies the procedure and could expand access to effective cartilage repair. The surgeon training program is a critical step toward commercializing this technology in Europe, potentially providing a new, minimally invasive treatment option for patients suffering from knee cartilage damage. For investors, this signals progress in Regentis's market entry strategy, which could impact the company's growth and the broader orthopedic regenerative medicine landscape.